白细胞介素-33/ST2受体轴在卵巢癌进展中的作用。
Role of the IL-33/ST2 receptor axis in ovarian cancer progression.
作者信息
Liu Ning, Chen Jintong, Zhao Yinghua, Zhang Mingyue, Piao Li, Wang Siqing, Yue Ying
机构信息
Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun, Jilin 130061, P.R. China.
Department of Cancer Immunology, The First Hospital of Jilin University, Changchun, Jilin 130061, P.R. China.
出版信息
Oncol Lett. 2021 Jul;22(1):504. doi: 10.3892/ol.2021.12765. Epub 2021 Apr 29.
Ovarian cancer remains a significant health problem for women in the world due to its diagnosis at advanced stages of disease and the high mortality rate of patients. To date, ovarian cancer is frequently treated with tumor reduction surgery followed by platinum/paclitaxel-based chemotherapy; however, most patients eventually develop relapsed disease. The mRNA expression levels of interleukin-33 (IL-33) and the suppressor of tumorigenicity 2 (ST2) receptor are significantly upregulated in ovarian cancer tissues and metastatic tumor lesions. In addition, IL-33 and ST2 expression has been associated with a poor overall survival in patients with epithelial ovarian cancer. The IL-33 receptor ST2 is expressed as both a membrane-anchored receptor (ST2L) activated by IL-33, and as a soluble variant that exhibits anti-inflammatory properties. In the present review, the functions of the IL-33/ST2L axis in cells and their aberrant expression levels in ovarian cancer were discussed. In addition, targeting their expression as a novel strategy for the control of ovarian cancer progression was emphasized.
由于卵巢癌在疾病晚期才被诊断出来且患者死亡率高，它仍然是全球女性面临的一个重大健康问题。迄今为止，卵巢癌的常见治疗方法是肿瘤减灭术，随后进行以铂类/紫杉醇为基础的化疗；然而，大多数患者最终会出现疾病复发。白细胞介素-33（IL-33）和致瘤性抑制因子2（ST2）受体的mRNA表达水平在卵巢癌组织和转移性肿瘤病灶中显著上调。此外，IL-33和ST2的表达与上皮性卵巢癌患者的总体生存率较差有关。IL-33受体ST2既表达为被IL-33激活的膜锚定受体（ST2L），也表达为具有抗炎特性的可溶性变体。在本综述中，讨论了IL-33/ST2L轴在细胞中的功能及其在卵巢癌中的异常表达水平。此外，强调了将靶向它们的表达作为控制卵巢癌进展的一种新策略。
Zotero 插件